Phospholamban Ablation Rescues Sarcoplasmic Reticulum Ca(2+) Handling but Exacerbates Cardiac Dysfunction in CaMKIIdelta(C) Transgenic Mice
Overview
Authors
Affiliations
Rationale: We previously showed that transgenic mice expressing Ca(2+)/calmodulin-dependent protein kinase II delta(C) (CaMKII-TG) develop dilated cardiomyopathy associated with increased ryanodine receptors (RyR2) phosphorylation, enhanced sarcoplasmic reticulum (SR) Ca(2+) leak and lowering of SR Ca(2+) load. We hypothesized that phospholamban (PLN) ablation would restore SR Ca(2+) load and prevent the decreased ventricular contractility, dilation and mortality seen in CaMKII-TG.
Objective: Our objectives were to generate CaMKII-TG mice lacking PLN, determine whether the maladaptive effects of cardiac CaMKIIdelta(C) expression were corrected, and establish the mechanistic basis for these changes.
Methods And Results: CaMKII-TG were crossed with PLN knockout (PLN-KO) mice to generate KO/TG mice. Myocytes from wild type (WT), CaMKII-TG, PLN-KO and KO/TG were compared. The decreased SR Ca(2+) load and twitch Ca(2+) transients seen in CaMKII-TG were normalized in KO/TG. Surprisingly the heart failure phenotype was exacerbated, as indicated by increased left ventricular dilation, decreased ventricular function, increased apoptosis and greater mortality. In KO/TG myocytes SR Ca(2+) sparks and leak were significantly increased, presumably because of the combined effects of restored SR Ca(2+) load and RyR2 phosphorylation. Mitochondrial Ca(2+) loading was increased in cardiomyocytes from KO/TG versus WT or CaMKII-TG mice and this was dependent on elevated SR Ca(2+) sparks. Cardiomyocytes from KO/TG showed poor viability, improved by inhibiting SR Ca(2+) release and mitochondrial Ca(2+) loading.
Conclusions: Normalizing cardiomyocyte SR Ca(2+) loading in the face of elevated CaMKII and RyR2 phosphorylation leads to enhanced SR Ca(2+) leak and mitochondrial Ca(2+) elevation, associated with exacerbated cell death, heart failure and mortality.
Conditional ablation of MCU exacerbated cardiac pathology in a genetic arrhythmic model of CPVT.
Deb A, Tow B, Hao J, Nguyen B, Gomez V, Stewart Jr J J Mol Cell Cardiol Plus. 2024; 10.
PMID: 39691471 PMC: 11651627. DOI: 10.1016/j.jmccpl.2024.100093.
Differential Downregulation of β-Adrenergic Receptor Signaling in the Heart.
Xu B, Bahriz S, Salemme V, Wang Y, Zhu C, Zhao M J Am Heart Assoc. 2024; 13(12):e033733.
PMID: 38860414 PMC: 11255761. DOI: 10.1161/JAHA.123.033733.
Dewenter M, Seitz T, Steinbrecher J, Westenbrink B, Ling H, Lehnart S ESC Heart Fail. 2024; 11(4):2191-2199.
PMID: 38616546 PMC: 11287324. DOI: 10.1002/ehf2.14772.
Kong L, Zhang Y, Ning J, Xu C, Wang Z, Yang J J Cell Mol Med. 2022; 26(20):5303-5314.
PMID: 36111515 PMC: 9575131. DOI: 10.1111/jcmm.17560.
CaMKII as a Therapeutic Target in Cardiovascular Disease.
Reyes Gaido O, Nkashama L, Schole K, Wang Q, Umapathi P, Mesubi O Annu Rev Pharmacol Toxicol. 2022; 63:249-272.
PMID: 35973713 PMC: 11019858. DOI: 10.1146/annurev-pharmtox-051421-111814.